Contact
searchSearch
HMP Global
Login

MULTIPLE MYELOMA

Noopur Raje, MD, Talks Anti-BCMA CAR-T Therapy for Relapsed/Refractory MM
Podcasts
Noopur Raje, MD, Talks Anti-BCMA CAR-T Therapy for Relapsed/Refractory MM
10/28/2020
In this podcast, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.
In this podcast, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.
In this podcast, Dr Raje...
10/28/2020
Oncology
Conference Insider
Triplet Combo Yields Significant Efficacy in Certain Patients With Lenalidomide-Refractory MM
10/23/2020
A triplet combo therapy comprising carfilzomib, lenalidomide, and dexamethasone has shown significant efficacy in patients with relapsed or refractory MM.
A triplet combo therapy comprising carfilzomib, lenalidomide, and dexamethasone has shown significant efficacy in patients with relapsed or refractory MM.
A triplet combo therapy...
10/23/2020
Oncology
BCMA-Directed CAR-T Therapy Shows Promise in Pretreated MM
Podcasts
BCMA-Directed CAR-T Therapy Shows Promise in Pretreated MM
10/22/2020
Jesus Berdeja, MD, discusses the results of the CARTITUDE-1 trial exploring BCMA-directed CAR-T therapy in relapsed/refractory MM.
Jesus Berdeja, MD, discusses the results of the CARTITUDE-1 trial exploring BCMA-directed CAR-T therapy in relapsed/refractory MM.
Jesus Berdeja, MD, discusses the...
10/22/2020
Oncology
Navigating the MM Treatment Landscape
Podcasts
Navigating the MM Treatment Landscape
10/20/2020
Natalie S. Callander, MD, discusses individualized treatment approaches for patients with relapsed or refractory MM.
Natalie S. Callander, MD, discusses individualized treatment approaches for patients with relapsed or refractory MM.
Natalie S. Callander, MD,...
10/20/2020
Oncology
Deep Sequencing Impacts Treatment Landscape for MM
Videos
Deep Sequencing Impacts Treatment Landscape for MM
01/03/2020
Gareth Morgan, MD, PhD, discusses deep sequencing and how it is improving the treatment landscape for MM.
Gareth Morgan, MD, PhD, discusses deep sequencing and how it is improving the treatment landscape for MM.
Gareth Morgan, MD, PhD,...
01/03/2020
Oncology
Videos
What is the Best Treatment Approach for Patients With MM Ineligible for Transplant?
11/13/2019
Vincent Rajkumar, MD, explains treatment approaches for patients with newly-diagnosed MM ineligible for transplant.
Vincent Rajkumar, MD, explains treatment approaches for patients with newly-diagnosed MM ineligible for transplant.
Vincent Rajkumar, MD, explains...
11/13/2019
Oncology
Videos
Should Monoclonal Antibodies Be Used in the Front-Line Setting for MM?
11/12/2019
Ajai Chari, MD, explains whether anti‑CS1, anti‑CD38, and bispecifics, should be used in the frontline setting for multiple myeloma.
Ajai Chari, MD, explains whether anti‑CS1, anti‑CD38, and bispecifics, should be used in the frontline setting for multiple myeloma.
Ajai Chari, MD, explains whether...
11/12/2019
Oncology
Videos
What is the Role of P53 in Deciding a Treatment Approach for Relapsed MM?
11/01/2019
Shaji Kumar, MD, discussed the role of the P53 gene in deciding the best treatment approach for patients with relapsed MM.
Shaji Kumar, MD, discussed the role of the P53 gene in deciding the best treatment approach for patients with relapsed MM.
Shaji Kumar, MD, discussed the...
11/01/2019
Oncology
Videos
What is the Best Treatment Approach for Smoldering Myeloma?
10/25/2019
Joseph Mikhael, MD, MEd, FRCPC, explains the best treatment approach for patients with smoldering myeloma.
Joseph Mikhael, MD, MEd, FRCPC, explains the best treatment approach for patients with smoldering myeloma.
Joseph Mikhael, MD, MEd, FRCPC,...
10/25/2019
Oncology
Videos
Immunotherapies in Multiple Myeloma
10/25/2019
David E. Avigan, MD discusses active immunotherapies for the treatment of multiple myeloma.
David E. Avigan, MD discusses active immunotherapies for the treatment of multiple myeloma.
David E. Avigan, MD discusses...
10/25/2019
Oncology

About

For nearly 2 decades, the Lymphoma, Leukemia & Myeloma Congress (formerly the Lymphoma & Myeloma Congress) has been recognized around the world as the most respected forum for industry-leading hematologic research.

It’s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.

This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use